Lombard Directors' Share Purchase
London, 16 January 2008 – Pursuant to the fundraising announced on 20 December 2007 and the approval by shareholders of the resolutions at the Extraordinary General Meeting held on 14 January 2008, the Directors of Lombard Medical have subscribed for, in aggregate, 784,282 ordinary shares of 2p each in the Company at the issue price of 14p on the same terms as the other investors. Details of their subsequent shareholdings are set out in the table below. Dealing in these new ordinary shares on the AIM market of the London Stock Exchange commenced today.
Number of shares subscribed for | Total holding | Percentage of issued share capital as enlarged by the fundraising | |
| Simon Neathercoat | 178,571 | 178,571 | 0.13 |
| Brian Howlett | 71,427 | 117,677 | 0.09 |
| Timothy Hall | 70,000 | 115,000 | 0.09 |
| Dr Timothy Cook | 71,428 | 71,428 | 0.05 |
| Craig Rennie | 178,571 | 178,571 | 0.13 |
| Prof Martin Rothman | 71,428 | 90,437 | 0.07 |
| Michael Stevens | 142,857 | 155,435 | 0.12 |
The issued share capital of Lombard Medical Technologies PLC, following the fundraising, is 133,979,931.
Enquiries
Lombard Medical Technologies PLC Tel: +44 (0) 1235 750 800
Simon Neathercoat, Non-Executive Chairman
Brian Howlett, Chief Executive Officer
Tim Hall, Finance Director
Financial Dynamics Tel: +44 (0) 20 7831 3113
David Yates / Susan Quigley
Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200
Juliet Thompson / Richard Potts
Notes to editors
About Lombard Medical:
Lombard Medical is a medical devices company developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is a stent graft for the treatment of aortic aneurysms, a balloon-like enlargement of the aorta, which, if untreated, may rupture, and cause death. Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in the US and the market is estimated to be worth approximately US$2 billion by 2010. Aorfix™ is currently being commercialised in the EU and US clinical trials are ongoing. The Company’s Polymer Coatings Division primarily develops polymer coatings for use in drug-eluting stents and has a number of research collaborations developing novel products for this US$6 billion market.
The Company, headquartered in Oxfordshire, with operations in Yorkshire, Ayrshire and Boston, USA,employs over 100 people.
Further background on the Company can be found at www.lombardmedical.com.